Arktus Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 11

Arktus Therapeutics General Information

Description

Developer of regenerative medical technology designed for knee cartilage regeneration. The company offers a combination of induced pluripotent stem cell research knowledge and three-dimensional printing technology to create a cell-derived cartilage implant that allows for a personalized treatment based on the individual's condition, enabling patients to recover their natural movement and experience a healthier life beyond the limitations of previous methods.

Contact Information

Website
www.arktustx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 448-5 Kajiicho, Kamigyo Ward
  • Room 106, Creation Core Kyoto Mikuruma
  • Kyoto, Kyoto 602-0841
  • Japan
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Vertical(s)
HealthTech
Corporate Office
  • 448-5 Kajiicho, Kamigyo Ward
  • Room 106, Creation Core Kyoto Mikuruma
  • Kyoto, Kyoto 602-0841
  • Japan

Arktus Therapeutics Timeline

202420252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arktus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 02-Jul-2026 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 22-Jul-2025 Completed Pre-Clinical Trials
4. Accelerator/Incubator 02-Jul-2025 Completed Pre-Clinical Trials
3. Accelerator/Incubator 24-Jul-2024 Completed Pre-Clinical Trials
2. Seed Round 17-Apr-2024 $2.63M $2.9M Completed Pre-Clinical Trials
1. Accelerator/Incubator 29-Nov-2023 $266K $266K Completed Pre-Clinical Trials
To view Arktus Therapeutics’s complete valuation and funding history, request access »

Arktus Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A
Class S1
Class S 13,333 $205.25 $205.25 1x $205.25 37.04%
To view Arktus Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Arktus Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
BIG Impact (Japan) Venture Capital Minority
Chushin Venture Capital Corporate Venture Capital Minority
Kyoto Capital Partners (Japan) Venture Capital Minority
MUFG Bank Lender/Debt Provider Minority
HELIOS Co., Ltd. Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Arktus Therapeutics FAQs

  • When was Arktus Therapeutics founded?

    Arktus Therapeutics was founded in 2023.

  • Where is Arktus Therapeutics headquartered?

    Arktus Therapeutics is headquartered in Kyoto, Japan.

  • What industry is Arktus Therapeutics in?

    Arktus Therapeutics’s primary industry is Therapeutic Devices.

  • Is Arktus Therapeutics a private or public company?

    Arktus Therapeutics is a Private company.

  • What is Arktus Therapeutics’s current revenue?

    The current revenue for Arktus Therapeutics is .

  • How much funding has Arktus Therapeutics raised over time?

    Arktus Therapeutics has raised $7.42M.

  • Who are Arktus Therapeutics’s investors?

    BIG Impact (Japan), Chushin Venture Capital, Kyoto Capital Partners (Japan), MUFG Bank, and HELIOS Co., Ltd. are 5 of 11 investors who have invested in Arktus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process